BrightSpring Health Services (BTSG) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue grew 26% year-over-year to $2.73 billion, led by strong performance in Pharmacy Solutions and Provider Services.

• Adjusted EBITDA for Q2 2024 was $139.1 million, up 16.7% year-over-year excluding the $30 million QIP received in 2023, which has now ended.

• Net income increased to $19.9 million, with EPS rising to $0.10 from $0.03 in Q2 2023.

• Full-year 2024 revenue and Adjusted EBITDA guidance were raised, reflecting confidence in continued growth and margin expansion.

• IPO completed in January 2024, raising $656.5 million in common stock and $389 million in tangible equity units, with proceeds used to repay debt and fund operations.

Financial highlights

• Pharmacy Solutions revenue was $2,114 million (up 32% year-over-year); Provider Services revenue was $616 million (up 8%).

• Pharmacy Solutions segment EBITDA was $94 million (up 18.7% year-over-year excluding QIP); Provider Services segment EBITDA was $86 million (up 16%).

• Gross profit for Q2 2024 was $389 million, up 14% year-over-year; gross margin was 14.3%, down from 17.2% in Q2 2023.

• Adjusted EPS for Q2 2024 was $0.10.

• Cash flow from operations was -$15 million for Q2 2024, but excluding a $90 million legal payment, it was $75 million.

Outlook and guidance

• 2024 revenue guidance raised to $10,450–$10,900 million, with Pharmacy Solutions expected at $8,000–$8,400 million and Provider Services at $2,450–$2,500 million.

• Adjusted EBITDA guidance increased to $570–$580 million, representing 12%–14% growth over 2023, excluding the QIP impact.

• Adjusted EBITDA margin expected to reach 5.4% for the year, with margin expansion anticipated in the second half.

• Growth rates and margin improvement expected to continue into 2025, with potential upside from M&A.

• Stable reimbursement environment and ongoing investments in automation, technology, and de novo locations to support future growth.